Uniphage is a biotech company that eliminates bacterial infections by combining the power of bacteriophages with artificial intelligence.
Uniphage is a biotech company that eliminates bacterial infections by combining the power of bacteriophages with artificial intelligence. Their first target disease is citrus greening, an incurable and debilitating disease that costs the United States more than $2 billion each year. Uniphage created the first commercially effective models for computationally predicting safe bacterial viruses against target bacterial infections, as well as discovered a variety of targets. This enables them to deliver new antimicrobial, safe, and precise products to market much more quickly.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 11, 2022 | Grant | $256K | 1 | National Science Foundation | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Science Foundation | Yes | Grant |